{
    "clinical_study": {
        "@rank": "65630", 
        "acronym": "REASSURE", 
        "arm_group": {
            "arm_group_label": "Cohort 1", 
            "description": "Single-arm cohort study"
        }, 
        "brief_summary": {
            "textblock": "Observational study in the routine clinical practice setting to evaluate the short and long\n      term safety profile of Radium-223 in metastatic castration resistant prostate cancer\n      patients and to evaluate the risk of developing second primary cancers."
        }, 
        "brief_title": "Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "December 2023", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostatic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Treatment decision to Radium-223 needs to be made independent from and before patient\n             enrollment in the study\n\n          -  Histologically or cytologically confirmed castration resistant adenocarcinoma of the\n             prostate with bone metastases\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Previously treated with Radium-223 for any reason\n\n          -  Currently treated in clinical trials including other Radium-223 studies\n\n          -  Planned for the systemic concomitant use of other radiopharmaceuticals for treatment\n             of prostate cancer or for other use"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with histologically or cytologically confirmed castration resistant\n        adenocarcinoma of the prostate with bone metastases for whom the treatment decision to\n        Radium-223 has been made independent from and before patient enrolment in the study."
            }
        }, 
        "enrollment": {
            "#text": "1334", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141438", 
            "org_study_id": "16913"
        }, 
        "intervention": {
            "arm_group_label": "Cohort 1", 
            "description": "An alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.", 
            "intervention_name": "Radium-223 dichloride (Xofigo, BAY88-8223)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Radium-223", 
            "Metastatic castration-resistant prostate cancer", 
            "CRPC", 
            "Phase IV", 
            "Safety study"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "number_of_groups": "1", 
        "official_title": "Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2023", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of developing second primary malignancies", 
                "safety_issue": "Yes", 
                "time_frame": "From study start to 7 years post last dose of Radium-223"
            }, 
            {
                "measure": "Incidence of treatment-emergent SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "From study start up to 30 days after the last administration of Radium-223"
            }, 
            {
                "measure": "Incidence of drug-related treatment-emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From study start up to 30 days after the last administration of Radium-223"
            }, 
            {
                "measure": "Incidence of drug-related SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "From study start to 7 years post last dose of Radium-223"
            }, 
            {
                "description": "Therapeutic/prevention measures/treatment modalities, Gr. 3/4 hematological toxicities (up to 6 months after last administration), platelet or WBC < lower limit of normal during treatment +30 days will be followed to resolution (up to 6 months after last administration), and febrile neutropenia and hemorrhage for patients who start subsequent chemotherapy will be assessed.", 
                "measure": "Bone marrow suppression", 
                "safety_issue": "Yes", 
                "time_frame": "From study start to 7 years post last dose of Radium-223"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141438"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From study start to 7 years post last dose of Radium-223"
            }, 
            {
                "measure": "The worst pain score and pain interference score over time as determined by patient responses on the \"Brief pain inventory short form\" (BPI-SF) questionnaire", 
                "safety_issue": "No", 
                "time_frame": "From study start to 6 months post last dose of Radium-223"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}